What are the causes of elevated hemoglobin with a negative Janus kinase 2 (JAK2) test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Causes of Elevated Hemoglobin with Negative JAK2 Marker

When JAK2 is negative in a patient with elevated hemoglobin, you must systematically evaluate for secondary causes of erythrocytosis, hereditary conditions, and rare JAK2-negative myeloproliferative disorders before labeling it as idiopathic erythrocytosis.

Primary Diagnostic Framework

The WHO diagnostic criteria acknowledge that while JAK2 mutations (V617F or exon 12) are present in approximately 95% of polycythemia vera cases, 5% of true PV cases may be JAK2-negative 1. However, JAK2-negative erythrocytosis more commonly represents secondary or hereditary causes 2, 3.

Immediate Assessment Steps

Measure serum erythropoietin (EPO) level - this single test provides critical diagnostic direction:

  • Subnormal EPO: Suggests primary erythrocytosis (JAK2-negative PV or EPOR mutations)
  • Normal/elevated EPO: Points toward secondary or hereditary causes 2, 3

Review historical hemoglobin/hematocrit values to distinguish:

  • Longstanding/lifelong elevation → hereditary causes
  • Recent/acquired elevation → secondary causes 2, 3

Major Causes by Category

1. Secondary Erythrocytosis (Acquired, Normal/High EPO)

Hypoxia-driven causes:

  • Chronic lung disease (COPD, sleep apnea)
  • Cyanotic heart disease
  • High-altitude dwelling
  • Chronic carbon monoxide exposure (smoking)
  • Renal artery stenosis (peripheral hypoxia) 1, 2, 3

EPO-producing conditions:

  • Renal cell carcinoma (most common tumor cause)
  • Hepatocellular carcinoma
  • Uterine leiomyomas
  • Cerebellar hemangioblastoma 2, 3

Drug-induced:

  • Testosterone/anabolic steroids
  • SGLT2 inhibitors (increasingly recognized cause)
  • Erythropoiesis-stimulating agents (ESAs) 2, 3

2. Hereditary Erythrocytosis (Longstanding, Variable EPO)

High oxygen-affinity hemoglobin variants (normal/high EPO):

  • Over 100 variants described
  • JAK2 V617F is definitively absent in these patients 4
  • Requires hemoglobin electrophoresis and P50 measurement

Oxygen-sensing pathway mutations (high EPO):

  • VHL (von Hippel-Lindau) - most common
  • PHD2 (prolyl hydroxylase 2)
  • HIF2A (hypoxia-inducible factor 2-alpha)
  • Chuvash polycythemia (VHL mutation) - notable for thrombotic tendency 2, 3

EPOR mutations (subnormal EPO):

  • Gain-of-function mutations in erythropoietin receptor
  • Uniquely associated with LOW EPO despite erythrocytosis 2, 3

Other rare causes:

  • 2,3-bisphosphoglycerate (2,3-BPG) deficiency
  • PIEZO1 mutations
  • Methemoglobinemia 3

3. JAK2-Negative Polycythemia Vera

If elevated hemoglobin meets WHO thresholds (Hgb >18.5 g/dL men, >16.5 g/dL women) with negative JAK2 testing, diagnosis requires 2 of 3 minor criteria 1:

  1. Bone marrow biopsy showing panmyelosis with trilineage proliferation
  2. Subnormal serum EPO
  3. Endogenous erythroid colony formation in vitro

Critical caveat: Bone marrow examination is mandatory when JAK2 is negative to establish PV diagnosis 5.

4. Apparent/Relative Polycythemia

  • Volume contraction (dehydration, diuretics)
  • Gaisbock syndrome (stress erythrocytosis)
  • Physiological outliers at upper normal range 3

Diagnostic Algorithm

Step 1: Confirm true erythrocytosis (not volume contraction)

  • Review serial hemoglobin/hematocrit measurements
  • Consider red cell mass measurement if uncertain

Step 2: Measure serum EPO level

Step 3a - If EPO is LOW:

  • Perform bone marrow biopsy to evaluate for JAK2-negative PV
  • Test for EPOR mutations
  • Consider endogenous erythroid colony assay

Step 3b - If EPO is NORMAL/HIGH:

  • Assess for hypoxia: pulse oximetry, arterial blood gas, sleep study
  • Evaluate for cardiopulmonary disease
  • Screen for renal artery stenosis (imaging)
  • Review medication list (testosterone, SGLT2-i)
  • Abdominal imaging for EPO-producing tumors

Step 4 - If longstanding/family history:

  • Hemoglobin P50 measurement (oxygen affinity)
  • Genetic testing panel: VHL, PHD2, HIF2A, EPOR
  • Consider expanded next-generation sequencing panel for hereditary erythrocytosis 3

Management Principles

Avoid cytoreductive therapy in secondary and hereditary erythrocytosis - this is fundamentally different from PV management 2, 3.

Phlebotomy should be symptom-driven, not hematocrit-threshold driven:

  • No evidence supports aggressive phlebotomy targets
  • Frequency determined by hyperviscosity symptoms (headache, dizziness, visual changes)
  • Exception: Chuvash polycythemia has documented thrombotic risk 2

Cardiovascular risk optimization:

  • Control hypertension, diabetes, hyperlipidemia
  • Smoking cessation
  • Low-dose aspirin (81 mg daily) often recommended, though evidence is limited 2, 3

Treat underlying cause when possible:

  • CPAP for sleep apnea
  • Revascularization for renal artery stenosis
  • Tumor resection for EPO-producing neoplasms
  • Discontinue causative medications

Common Pitfalls

  1. Assuming all erythrocytosis is PV: JAK2-negative cases are more likely secondary/hereditary than true PV
  2. Over-phlebotomizing: Can worsen symptoms and quality of life without proven benefit in non-PV erythrocytosis
  3. Missing drug causes: Always review SGLT2 inhibitors, testosterone, and ESAs 3
  4. Inadequate workup: Labeling as "idiopathic" without measuring EPO, checking family history, or considering hereditary causes
  5. Inappropriate cytoreduction: Using hydroxyurea or other agents in secondary erythrocytosis increases toxicity without benefit

If comprehensive workup is negative, consider expanded genetic testing with next-generation sequencing panels for hereditary erythrocytosis, as molecular advances continue to reclassify "idiopathic" cases 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.